DiaMedica Therapeutics Inc. — Form 10-Q Summary
Business Context and Reporting Period
This quarterly report covers the three and six months ended June 30, 2023. DiaMedica is a clinical-stage biotechnology company developing DM199, a recombinant human tissue kallikrein-1 protein, primarily for acute ischemic stroke (AIS) and cardio-renal disease (CRD). The company has no commercial products and has not generated product revenue.
Financial Position and Results
| Metric | Three Months Ended June 30 | Six Months Ended June 30 |
|---|---|---|
| Revenue | No product revenue | No product revenue |
| Research and development expense | $2.5 million | $6.2 million |
| General and administrative expense | $2.2 million | $4.1 million |
| Operating loss | $4.7 million | $10.3 million |
| Other income, net | $0.3 million | $0.5 million |
| Net loss | $4.5 million | $9.7 million |
| Net loss per share | $0.16 | $0.36 |
| Net cash used in operating activities | Not separately provided | $10.1 million |
Profit margins are not meaningful because the company has no revenue and remains loss-making. The accumulated deficit was $105.9 million at June 30, 2023. Share-based compensation was $0.8 million for the six-month period.
At June 30, 2023, cash and cash equivalents were $5.8 million, marketable securities were $54.8 million, and total liquidity was $60.7 million. Working capital was $39.3 million, total assets were $62.1 million, and shareholders’ equity was $59.7 million. The company had no credit facilities or material debt; liabilities consisted primarily of accounts payable, accrued liabilities, and lease obligations.
Material Changes Versus Prior Comparable Period
- Six-month R&D expense increased to $6.2 million from $3.9 million, primarily because of the in-use stability study supporting removal of the ReMEDy2 clinical hold, the Phase 1C study, manufacturing and process-development activities, REDUX data analysis, and higher clinical personnel costs.
- Six-month G&A expense increased to $4.1 million from $3.0 million, driven primarily by legal fees related to litigation with PRA Netherlands, higher personnel costs, professional fees, and share-based compensation.
- Six-month net loss increased to $9.7 million from $6.9 million, and operating cash use increased to $10.1 million from $6.4 million.
- Cash flow from investing activities changed to a use of $25.6 million from a source of $4.7 million, reflecting the timing of purchases and maturities of marketable securities.
- The company raised approximately $36.9 million of net proceeds through April and June 2023 private placements. The June placement included 11.0 million shares and materially increased shares outstanding to 37.9 million at June 30, 2023 from 26.4 million at December 31, 2022.
Guidance, Outlook, Risks, Contingencies, and Unusual Items
- In June 2023, the FDA removed the clinical hold on the Phase 2/3 ReMEDy2 AIS trial, allowing preparations to resume the trial. The adaptive trial is designed to enroll approximately 350 participants at up to 75 U.S. sites.
- The hold followed three unexpected clinically significant hypotension events after intravenous DM199 dosing. The company submitted additional stability data and protocol-supporting information to the FDA.
- Management expects slower-than-planned site activation and enrollment could continue because of staffing shortages, clinical-site constraints, and participant logistics. The company plans to bring some site-engagement activities in-house and use a clinical services consulting firm.
- The company is finalizing data analyses and the clinical study report for the Phase 2 REDUX CRD trial while evaluating next steps for the CRD program.
- Management expects current cash, cash equivalents, and marketable securities to fund planned operations for at least 12 months from issuance of the financial statements, including resumption of ReMEDy2 and REDUX activities. The company also expects to require substantial additional capital and may seek equity, debt, collaboration, or licensing financing.
- Key risks include unsuccessful or delayed clinical trials, regulatory setbacks, adverse DM199 safety findings, limited enrollment, manufacturing and commercialization challenges, dilution from future financing, and inability to obtain funding on acceptable terms.
- The company is pursuing litigation against ICON/PRA Netherlands concerning access to clinical-study documents and data. A Dutch court ruled in April 2023 in DiaMedica’s favor regarding ownership and access; ICON/PRA appealed in June 2023. The filing states that no current legal proceeding is expected to materially affect financial position or results, but outcomes remain uncertain.
- The company disclosed heightened risks from bank failures and broader banking or capital-market disruptions, although it did not have deposits at Silicon Valley Bank, Signature Bank, or First Republic Bank.
Important Facts for Investors to Verify
- Whether ReMEDy2 actually resumed, and the pace of site activation and patient enrollment after the clinical hold was removed.
- Additional safety, efficacy, or regulatory developments concerning DM199, including any recurrence of hypotension events.
- Results and strategic decisions from the REDUX CRD trial and the timing of future clinical milestones.
- Monthly cash burn, updated liquidity, and the timing and terms of any additional financing.
- The potential dilution from outstanding options, deferred stock units, restricted stock units, and warrants, totaling approximately 5.6 million reserved shares at June 30, 2023.
- The status and financial implications of the ICON/PRA Netherlands litigation and related clinical-data access.